Research output: Contribution to journal › Article › peer-review
Pharmacological characterization of a novel putative nootropic beta-alanine derivative, MB-005, in adult zebrafish. / Kolesnikova, Tatiana O; Galstyan, David S; Demin, Konstantin A; Barabanov, Mikhail A; Pestov, Alexander V; S de Abreu, Murilo; Strekalova, Tatyana; Kalueff, Allan V.
In: Journal of Psychopharmacology, Vol. 36, No. 7, 07.2022, p. 892-902.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Pharmacological characterization of a novel putative nootropic beta-alanine derivative, MB-005, in adult zebrafish
AU - Kolesnikova, Tatiana O
AU - Galstyan, David S
AU - Demin, Konstantin A
AU - Barabanov, Mikhail A
AU - Pestov, Alexander V
AU - S de Abreu, Murilo
AU - Strekalova, Tatyana
AU - Kalueff, Allan V
N1 - Publisher Copyright: © The Author(s) 2022.
PY - 2022/7
Y1 - 2022/7
N2 - BACKGROUND: Cognitive deficits represent an urgent biomedical problem, and are commonly reduced by nootropic drugs. Animal models, including both rodents and zebrafish, offer a valuable tool for studying cognitive phenotypes and screening novel nootropics. Beta-alanine and its derivatives have recently been proposed to exert nootropic activity.AIMS: This study aimed to characterize putative nootropic profile of a novel β-alanine analogue, 1,3-diaminopropane (MB-005), in adult zebrafish.METHODS: Nootropic profile of MB-005 was assessed in adult zebrafish in the novel tank and conditioned place aversion (CPA) tests acutely, and in cued-learning plus-maze (PMT) tests chronically.RESULTS/OUTCOMES: MB-005 did not alter zebrafish anxiety-like behavior or monoamine neurochemistry acutely, improved short-term memory in the CPA test, but impaired cognitive performance in both CPA and PMT tests chronically.CONCLUSIONS/INTERPRETATION: This study reveals high sensitivity of zebrafish cognitive phenotypes to MB-005, suggesting it as a potential novel cognitive enhancer acutely, but raises concerns over its cognitive (and, possibly, other) side-effects chronically.
AB - BACKGROUND: Cognitive deficits represent an urgent biomedical problem, and are commonly reduced by nootropic drugs. Animal models, including both rodents and zebrafish, offer a valuable tool for studying cognitive phenotypes and screening novel nootropics. Beta-alanine and its derivatives have recently been proposed to exert nootropic activity.AIMS: This study aimed to characterize putative nootropic profile of a novel β-alanine analogue, 1,3-diaminopropane (MB-005), in adult zebrafish.METHODS: Nootropic profile of MB-005 was assessed in adult zebrafish in the novel tank and conditioned place aversion (CPA) tests acutely, and in cued-learning plus-maze (PMT) tests chronically.RESULTS/OUTCOMES: MB-005 did not alter zebrafish anxiety-like behavior or monoamine neurochemistry acutely, improved short-term memory in the CPA test, but impaired cognitive performance in both CPA and PMT tests chronically.CONCLUSIONS/INTERPRETATION: This study reveals high sensitivity of zebrafish cognitive phenotypes to MB-005, suggesting it as a potential novel cognitive enhancer acutely, but raises concerns over its cognitive (and, possibly, other) side-effects chronically.
KW - Nootropics
KW - memory
KW - piracetam
KW - zebrafish
KW - β-alanine
KW - Behavior, Animal
KW - Cues
KW - beta-Alanine/pharmacology
KW - Animals
KW - Nootropic Agents/pharmacology
KW - Zebrafish
KW - Anxiety
UR - http://www.scopus.com/inward/record.url?scp=85132416523&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/2ee94f96-34f6-371d-b70c-8dc919ad91a5/
U2 - 10.1177/02698811221098192
DO - 10.1177/02698811221098192
M3 - Article
C2 - 35713386
VL - 36
SP - 892
EP - 902
JO - Journal of Psychopharmacology
JF - Journal of Psychopharmacology
SN - 0269-8811
IS - 7
ER -
ID: 96511795